Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on February 14, 2013, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2012. This filing primarily serves to make public the detailed results, which were issued via a press release on the same date. Investors should note that this 8-K is a procedural filing, and the substantive information regarding Regeneron's financial performance and operational highlights for the period is contained within the press release attached as Exhibit 99.1. The press release itself would contain key metrics such as revenue, net income, earnings per share, and updates on product development and commercialization efforts. Accessing Exhibit 99.1 is crucial for a complete understanding of the company's performance during that quarter and fiscal year.
Key Highlights
- 1Filing of an 8-K on February 14, 2013, to report financial and operating results.
- 2Results announced are for the fourth quarter and full year ended December 31, 2012.
- 3The primary content is a press release, furnished as Exhibit 99.1.
- 4Item 2.02 (Results of Operations and Financial Condition) is the relevant section for this announcement.
- 5Item 9.01 (Financial Statements and Exhibits) lists the press release as an exhibit.
- 6This filing is procedural, directing investors to the attached press release for detailed financial data.